Kitov Pharmaceuticals has expanded its pipeline through the acquisition of TyrNovo, a privately held developer of novel small molecules in the immuno-oncology therapeutic field, for $3.8 million. The expansion into developing immuno-oncology drugs comes as Kitov plans to file its New Drug Application (NDA) with the FDA for its flagship combination drug, KIT-302, which is intended to treat osteoarthritis pain and hypertension simultaneously, in Q1 2017, with commercial launch anticipated for t...